Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06623201 · ClinicalTrials.gov registry record · Phase 1
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
A Phase 1 study of Basal Cell Carcinoma (BCC), sponsored by Nathalie Zeitouni.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06623201 is a Phase 1 study of Basal Cell Carcinoma (BCC) that is actively recruiting participants, run by Nathalie Zeitouni. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06623201, a Phase 1 study of Basal Cell Carcinoma (BCC), is actively recruiting participants, sponsored by Nathalie Zeitouni.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions. Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatment can cause scarring. Photodynamic therapy uses light along with a drug applied to the skin to kill the cancer cells and cause them to break apart. The light used can cause the skin to feel warm, but does not cause scarring.
Conditions Studied
Interventions
- DRUG aminolevulinic acid HCL (ALA)
- DEVICE BLU-U device model 4170E
Study Locations (1)
Arizona
- Medical Dermatology Specialists - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06623201
The ClinicalTrials.gov registry entry for NCT06623201 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nathalie Zeitouni, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Basal Cell Carcinoma (BCC) appearing as the primary indexed condition, and to 2 interventions - of which aminolevulinic acid HCL (ALA) is the first listed.
NCT06623201 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06623201 about?
NCT06623201 is a clinical study titled "Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas". This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions. Basal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatme...
What is the current status of trial NCT06623201?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-10-07. Estimated completion is 2026-12-01.
What conditions does trial NCT06623201 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma (BCC).
What interventions are being tested in trial NCT06623201?
The interventions under investigation include: aminolevulinic acid HCL (ALA) (DRUG), BLU-U device model 4170E (DEVICE).
Who is sponsoring clinical trial NCT06623201?
This trial is sponsored by Nathalie Zeitouni, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06623201 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma (BCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.